Severe Hypertriglyceridemia
Conditions
Interventions
DRUG: Solbinsiran(Other Name: LY3561774)
Administered SC
DRUG: Placebo
Administered SC
(Study Arms)
Experimental: Solbinsiran
Participants will receive solbinsiran subcutaneously (SC)
Interve
Sponsors
Masaki Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - History of fasting triglyceride levels of >=500 milligrams per deciliter (mg/dL), based on medical history - Fasting triglyceride level >=500 mg/dL at two separate visits during screening (at least 7 days apart) - Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive)
Exclusion criteria
Exclusion criteria: - Have had a major atherosclerotic cardiovascular event within the past 3 months prior to screening - Have a history of acute pancreatitis within 12 months prior to screening - Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome - Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral vector-mediated, or other genetic modification techniques - Have a history of chronic alcohol abuse within 3 years prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in Triglycerides [ Time Frame: Baseline, Weeks 16-24 (Time-Average) | — |
Countries
Canada, China, Japan, United States
Contacts
Public ContactTrial Guide Call Center
Eli Lilly Japan K.K.
Outcome results
None listed